成人X站

A new COVID-19 treatment is on the horizon. Drug manufacturer Merck鈥檚 COVID treatment 鈥� available in pill form 鈥� has been submitted to the U.S. Food and Drug Administration for emergency-use authorization.

The antiviral drug molnupiravir could be taken at home, which would help reduce the burden on hospitals as most current COVID intervention treatments require IV or injection.

Dr. Gordon Cohen appeared on 成人X站 Radio鈥檚 Seattle’s Morning News to break down Merck’s new medication, answer questions about its clinical trial period, and speak to how it might change the public health response to the COVID pandemic. He likened the drug to 鈥淭amiflu鈥� in terms of its potential easy consumer access and availability.

鈥淎ll along, I thought that the answer wasn’t necessarily a vaccine, but rather a therapeutic, first of all,鈥� Cohen said. 鈥淛ust by looking at our historic compliance with vaccines, especially the flu vaccine, it’s pretty poor. Annually, just under 40% of people get the flu vaccine.”

鈥淣ow there’s a therapeutic, and I’ve always thought that this would be what was ultimately necessary. You would need something that was inexpensive that could be taken at home, in a pill form, that would treat COVID,” he added. “In fact, here it is. Merck has finally announced the development of the first of what will probably be a series of pills that will come out from different manufacturers.鈥�

Merck asks US FDA to authorize promising anti-COVID pill

Cohen touched on the study to determine the medication鈥檚 efficacy: how the study actually ended early because the drug was so effective that it was deemed unethical to give the control group a placebo. He touched on the drug鈥檚 significance within the context of its potential to treat COVID cases from those who refuse a vaccine.

鈥淭he interesting thing is that this entire group was unvaccinated people,鈥� Cohen continued. 鈥淭hat’s part of the reason that there was necessity to end the study early.鈥�

Dr. Cohen addressed a concern about COVID vaccines 鈥� that their development was fast in comparison to the traditional length at which vaccines are researched and produced 鈥� and how that same concern might apply to Merck’s treatment, which itself had an expedited development period.

鈥淭his drug was specifically developed for COVID,鈥� Cohen added. 鈥淣ow the thing is that, [of] people who have been resistant to get the vaccine, one of the complaints has been, 鈥榯he vaccine came out too fast, and it wasn’t studied on enough people, so who knows what’s going to happen.鈥� If they believe in what they’re saying about the vaccine, then they’re going to have the same complaint about this.鈥�

Listen to Seattle’s Morning News weekday mornings from 5 – 9 a.m. on 成人X站 Radio, 97.3 FM. Subscribe to the podcast here.